The Uromigos
The Uromigos
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Não deixe de visitar o site do podcast e apoiar quem o produz: www.uromigos.org
Autor
The Uromigos
Categoria
Site do podcast
Último episódio
5 de out de 2026
Onde ouvir?
Podcasts no app Replaio Radio Em breveOs podcasts estão chegando ao app. Instale agora e seja o primeiro a descobrir um jeito totalmente novo de curtir podcasts
Episódios
Episode 342: ESMO 2024 Preview with Silke Gillessen 03.09.2024 32:24
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
Episode 341: Hormone Resistance in Prostate Cancer 27.08.2024 33:05
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
Episode 340: Cancer Immunity Cycle Update 19.08.2024 41:50
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU 09.08.2024 18:37
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More 06.08.2024 25:39
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
Episode 337: Updated NCCN Guidelines in RCC 30.07.2024 42:38
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer 24.07.2024 35:35
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
Episode 335: Novel immune therapies for renal cancer 19.07.2024 37:31
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
Episode 333: The Uromigos Cup - The Netherlands 05.07.2024 26:20
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
Episode 332: The Uromigos Cup - Germany's Entry 26.06.2024 35:55
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
Episode 331: AUA 2024 NMIBC Highlights 21.06.2024 33:56
Aditya Bagrodia describes three new drugs/studies in NMIBC.
Episode 330: ASCO 2024 Highlights 10.06.2024 52:47
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies 05.06.2024 26:32
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates 04.06.2024 24:02
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
Episode 326 ASCO24: KIM-1 in Renal Cancer 03.06.2024 18:08
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer 03.06.2024 33:44
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC 02.06.2024 20:43
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
Episode 323 ASCO24: TDXD in Bladder Cancer 02.06.2024 29:47
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC) 02.06.2024 22:16
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original? 01.06.2024 23:25
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
Episode 320: Team Canada's entry for the Uromigos Cup 25.05.2024 23:30
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
Episode 319: ASCO 2024: A Preview of GU Data 19.05.2024 33:49
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases 13.05.2024 31:59
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
Episode 317: AUA 2024 Preview with the AUA Secretary 01.05.2024 22:16
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
Episode 316: APCCC 2024 Summary with Silke Gillessen 28.04.2024 41:11
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
Podcasts parecidos
O Replaio não é o publicador dos podcasts; os nomes dos programas, as capas e o áudio pertencem aos seus autores e são distribuídos por feeds RSS públicos